ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.71 million
Profitability
Miscellaneous
Employees32
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) issued its earnings results on Wednesday, October, 31st. The biotechnology company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biotechnology company earned $4.98 million during the quarter, compared to analyst estimates of $2.44 million. During the same period last year, the business earned ($0.09) EPS. View ArQule's Earnings History.
When is ArQule's next earnings date?
What guidance has ArQule issued on next quarter's earnings?
ArQule issued an update on its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided EPS guidance of $-0.17--0.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.12. The company issued revenue guidance of $24-25 million, compared to the consensus revenue estimate of $22.66 million.
What price target have analysts set for ARQL?
5 equities research analysts have issued 12 month price targets for ArQule's stock. Their forecasts range from $7.00 to $7.00. On average, they expect ArQule's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Has ArQule been receiving favorable news coverage?
News articles about ARQL stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ArQule earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Are investors shorting ArQule?
ArQule saw a drop in short interest in the month of December. As of December 14th, there was short interest totalling 7,751,941 shares, a drop of 17.3% from the November 30th total of 9,378,896 shares. Based on an average trading volume of 1,552,959 shares, the short-interest ratio is currently 5.0 days. Approximately 7.9% of the shares of the company are short sold. View ArQule's Current Options Chain.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), Cambrex (CBM), Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Arrowhead Pharmaceuticals (ARWR), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Wave Life Sciences (WVE) and Myovant Sciences (MYOV).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 56)
- Mr. Robert J. Weiskopf, CFO & Treasurer (Age 68)
- Dr. Brian Schwartz, Chief Medical Officer (Age 57)
- Ms. Dawn Schottlandt, VP of Investor Relations & Corp. Communications
Who are ArQule's major shareholders?
ArQule's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which major investors are buying ArQule stock?
ARQL stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Meeder Asset Management Inc.. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $3.70.
How big of a company is ArQule?
ArQule has a market capitalization of $403.28 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
